Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Sanjeeva Dissanayake"'
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 12 (2018)
Background: The efficacy and safety of fluticasone propionate/formoterol fumarate pressurized metered-dose inhaler (pMDI) (fluticasone/formoterol; Flutiform ® ; 100/10 µg b.i.d.) was compared with fluticasone propionate (Flixotide ® Evohaler ® pM
Externí odkaz:
https://doaj.org/article/26bdc797c91747a4895dfc8a6d6b06b1
Autor:
Sanjeeva Dissanayake, Jason Suggett
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 12 (2018)
Valved holding chambers (VHCs) reduce the need for inhalation-actuation coordination with pressurized metered dose inhalers (pMDIs), reduce oropharyngeal drug deposition and may improve lung deposition and clinical outcomes compared to pMDIs used alo
Externí odkaz:
https://doaj.org/article/c9319e9546414ca48fa749da0533b0c5
Publikováno v:
Journal of Aerosol Medicine and Pulmonary Drug Delivery. 36:65-75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a6dc34ff6154c10907d232960f8ca16
https://doi.org/10.1089/jamp.2022.0064
https://doi.org/10.1089/jamp.2022.0064
Publikováno v:
Clinical Drug Investigation. 38:313-318
For more than a decade, urinary free cortisol corrected for creatinine (OUFCC) has been used to assess the systemic bioactivity of inhaled corticosteroids in children with asthma. Paediatric normative ranges, however, have not been established. The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9033e33daafa53fabf58ce7dccee54
https://doi.org/10.1007/s40261-017-0609-x
https://doi.org/10.1007/s40261-017-0609-x
Publikováno v:
Journal of Aerosol Medicine and Pulmonary Drug Delivery. 30:373-380
Fluticasone propionate/formoterol (FP/FORM) is a pressurized metered-dose inhaler (pMDI; FlutiformTo compare short-term growth in asthmatic children treated with FP/FORM, FP pMDI with valved holding chamber, and beclomethasone dipropionate (BDP) in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1283f3f0e03addd6fcd79cbca7d352b5
https://doi.org/10.1089/jamp.2016.1335
https://doi.org/10.1089/jamp.2016.1335
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 12 (2018)
Therapeutic Advances in Respiratory Disease
Therapeutic Advances in Respiratory Disease
Background: The efficacy and safety of fluticasone propionate/formoterol fumarate pressurized metered-dose inhaler (pMDI) (fluticasone/formoterol; Flutiform®; 100/10 µg b.i.d.) was compared with fluticasone propionate (Flixotide® Evohaler® pMDI;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::259d45ec770ed33c394121f3dc0fc9da
https://doaj.org/article/26bdc797c91747a4895dfc8a6d6b06b1
https://doaj.org/article/26bdc797c91747a4895dfc8a6d6b06b1
Publikováno v:
Airway Pharmacology and Treatment.
Background: Two-stage (S1, S2) adaptive design study to compare systemic BA and PD of FP and FORM via the BTI (Flutiform® K-haler®), and pMDI with (+S) or without a spacer (EudraCT: 2013-000045-39). Methods: Single-dose, randomised, open-label cros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30d8ba1715399fc51602a0566ba1970c
https://doi.org/10.1183/1393003.congress-2017.pa3950
https://doi.org/10.1183/1393003.congress-2017.pa3950
Publikováno v:
Airway Pharmacology and Treatment.
Background: This study aimed to show that pulmonary BA of FP and FORM via the BTI (Flutiform® K‑haler®) was no less than via pMDI without a spacer, to establish a bridge from the efficacy of the pMDI to the BTI (EudraCT: 2012-003728-19). Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a55b6cd8457534b7fe06cc07ba6c2f6
https://doi.org/10.1183/1393003.congress-2017.pa523
https://doi.org/10.1183/1393003.congress-2017.pa523
Publikováno v:
Pulmonary pharmacologytherapeutics. 48
Introduction The European Medicines Agency (EMA) requires that a specific valved holding chamber (VHC) is designated for use with a given pressurised metered dose inhaler (pMDI). No other regulatory authorities impose similar requirements, implying t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f93fe5b5eb7ac1a809e7c55c9b7870f9
https://pubmed.ncbi.nlm.nih.gov/29024795
https://pubmed.ncbi.nlm.nih.gov/29024795
Autor:
Birgit Grothe, Kirsten Kaiser, Tammy McIver, Sanjeeva Dissanayake, Adel H. Mansur, Alberto Papi, Tetyana Pertseva
Publikováno v:
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Background: A primary goal of asthma management is the reduction of exacerbation risk. We assessed the occurrence of oral corticosteroid-requiring exacerbations (OCS exacerbations) with long-term fluticasone/formoterol therapy, and compared it with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9e37c6c9fa211f08dbfb1bccb15cf6
http://hdl.handle.net/11392/2352005
http://hdl.handle.net/11392/2352005
